We're making the next batch
Ships in ~7 days or less
These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.
Third-party tested for purity, identity, and quantity.
This research blend is typically supplied as a lyophilized (freeze-dried) powder containing both peptides at defined molar or mass ratios, with each component verified to ≥98% purity by HPLC analysis. A Certificate of Analysis (CoA) documenting purity, identity (mass spectrometry confirmation), and endotoxin levels is available for each lot, consistent with standards expected for laboratory research reagents.
This material is characterized in standard in vitro laboratory systems (for example, receptor-expressing cell lines and biochemical assays). It is supplied for in vitro laboratory research use only and is not intended for human or animal use.
BPC-157 research has focused on its interactions with the VEGFR2 (KDR) signaling pathway, nitric oxide synthase (NOS) systems, the FAK-paxillin pathway in epithelial and endothelial cells, and EGR-1 transcription factor modulation. TB-500 research (based on the parent Thymosin β4 molecule) centers on its role as a G-actin sequestering protein through binding to profilin, its modulation of the Ac-SDKP–ACE axis, and downstream effects on cell migration and anti-inflammatory signaling. These distinct target profiles make the blend of interest to researchers studying overlapping or synergistic pathway engagement.
Quality controlled from start to finish. No outsourcing.
This blend combines BPC-157 (a 15-amino-acid gastric peptide) and TB-500 (a 43-amino-acid thymosin beta-4 fragment). Supplied as a research reagent for in vitro laboratory assays only; not for human or animal use.
